Vincent Bordas

1.5k total citations
14 papers, 836 citations indexed

About

Vincent Bordas is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Vincent Bordas has authored 14 papers receiving a total of 836 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 4 papers in Organic Chemistry and 2 papers in Pharmacology. Recurrent topics in Vincent Bordas's work include Wnt/β-catenin signaling in development and cancer (5 papers), Fibroblast Growth Factor Research (3 papers) and Synthesis and Characterization of Heterocyclic Compounds (2 papers). Vincent Bordas is often cited by papers focused on Wnt/β-catenin signaling in development and cancer (5 papers), Fibroblast Growth Factor Research (3 papers) and Synthesis and Characterization of Heterocyclic Compounds (2 papers). Vincent Bordas collaborates with scholars based in United Kingdom, Switzerland and China. Vincent Bordas's co-authors include Jason Witherington, Robert W. Ward, David G. Smith, Brian P. Slingsby, Robert J. Ife, Markus Wartmann, Vito Guagnano, Pascal Furet, Mickaël Le Douget and Deirdre M. B. Hickey and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Molecular Cancer Therapeutics.

In The Last Decade

Vincent Bordas

14 papers receiving 802 citations

Peers

Countries citing papers authored by Vincent Bordas

Since Specialization

Citations

This map shows the geographic impact of Vincent Bordas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Bordas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Bordas more than expected).

Fields of papers citing papers by Vincent Bordas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent Bordas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Bordas. The network helps show where Vincent Bordas may publish in the future.

Co-authorship network of co-authors of Vincent Bordas

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent Bordas. A scholar is included among the top collaborators of Vincent Bordas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent Bordas. Vincent Bordas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition 2022 ·ChemMedChem ·Pascal Furet, Vincent Bordas, Mickaël Le Douget, Bahaâ Salem, Yannick Mesrouze, Patricia Imbach‐Weese, Holger Sellner, (unknown), Nicolas Soldermann, Emilie A. Chapeau, Markus Wartmann, Clemens Scheufler, César Fernández Fernández, Joerg Kallen, Vito Guagnano, Patrick Chêne, Tobias Schmelzle	26
2	Abstract 854: Patient stratification strategies for NVP-BGJ398, a selective pan-FGFR inhibitor in phase I clinical trials 2012 ·Cancer Research ·Diana Graus Porta, Vito Guagnano, Christelle Stamm, (unknown), Audrey Kauffmann, Yao Yao, Thomas Brümmendorf, Vincent Bordas, Mickaël Le Douget, Yun Zhang, Zhi Chen, Moriko Ito, Fang Li, John E. Monahan, Alex Gaither, Jason Borawski, Christopher J. Wilson, K. Venkatesan, Francesco Hofmann, William R. Sellers	1
3	Abstract B246: NVP-BGJ398: A potent and selective inhibitor of the fibroblast growth factor receptor family. 2011 ·Molecular Cancer Therapeutics ·Vito Guagnano, Diana Graus Porta, Vincent Bordas, Mickaël Le Douget, Christelle Stamm, Pascal Furet, Carsten Spanka, Markus Wartmann, Herbert Schmid, (unknown), Peter Drueckes, Dirksen E. Bussiere, Tinya J. Abrams, Katherine G. Rendahl, Isabelle Bernard‐Pierrot, François Radvanyi	1
4	Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase 2011 ·Journal of Medicinal Chemistry ·Vito Guagnano, Pascal Furet, Carsten Spanka, Vincent Bordas, Mickaël Le Douget, Christelle Stamm, Josef Brueggen, Michael Rugaard Jensen, Christian Schnell, Herbert Schmid, Markus Wartmann, Joerg Berghausen, Peter Drueckes, Alfred Zimmerlin, Dirksen E. Bussiere, Jeremy Murray, Diana Graus Porta	378
5	Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists 2006 ·Bioorganic & Medicinal Chemistry Letters ·Jason Witherington, (unknown), Vincent Bordas, Richard L. Elliott, Alessandra Gaiba, Neil Garton, (unknown), A. Naylor, David G. Smith, David J. Spalding, Andrew K. Takle, Robert W. Ward	6
6	Pyridone derivatives as potent and selective VLA-4 integrin antagonists 2006 ·Bioorganic & Medicinal Chemistry Letters ·Jason Witherington, Vincent Bordas, Alessandra Gaiba, (unknown), A. Naylor, (unknown), David G. Smith, Andrew K. Takle, Robert W. Ward	12
7	6-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3) 2003 ·Bioorganic & Medicinal Chemistry Letters ·Jason Witherington, Vincent Bordas, Alessandra Gaiba, Neil Garton, A. Naylor, (unknown), Brian P. Slingsby, David G. Smith, Andrew K. Takle, Robert W. Ward	103
8	5-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3) 2003 ·Bioorganic & Medicinal Chemistry Letters ·Jason Witherington, Vincent Bordas, Stephen L. Garland, Deirdre M. B. Hickey, Robert J. Ife, John Liddle, Martin Saunders, David G. Smith, Robert W. Ward	95
9	6-Heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3) 2003 ·Bioorganic & Medicinal Chemistry Letters ·Jason Witherington, Vincent Bordas, Alessandra Gaiba, A. Naylor, (unknown), Brian P. Slingsby, David G. Smith, Andrew K. Takle, Robert W. Ward	73
10	5-Aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3) 2003 ·Bioorganic & Medicinal Chemistry Letters ·Jason Witherington, Vincent Bordas, David Haigh, Deirdre M. B. Hickey, Robert J. Ife, (unknown), Brian P. Slingsby, David G. Smith, Robert W. Ward	98
11	5‐Aryl‐pyrazolo[3,4‐b]pyridines: Potent Inhibitors of Glycogen Synthase Kinase‐3 (GSK‐3). 2003 ·ChemInform ·Jason Witherington, Vincent Bordas, Stephen L. Garland, Deirdre M. B. Hickey, Robert J. Ife, John Liddle, Martin Saunders, David G. Smith, Robert W. Ward	1
12	5‐Aryl‐pyrazolo[3,4‐b]pyridazines: Potent Inhibitors of Glycogen Synthase Kinase‐3 (GSK‐3). 2003 ·ChemInform ·Jason Witherington, Vincent Bordas, David Haigh, Deirdre M. B. Hickey, Robert J. Ife, (unknown), Brian P. Slingsby, David G. Smith, Robert W. Ward	2
13	6‐Aryl‐pyrazolo[3,4‐b]pyridines: Potent Inhibitors of Glycogen Synthase Kinase‐3 (GSK‐3). 2003 ·ChemInform ·Jason Witherington, Vincent Bordas, Alessandra Gaiba, Neil Garton, A. Naylor, (unknown), Brian P. Slingsby, David G. Smith, Andrew K. Takle, Robert W. Ward	5
14	Conformationally Restricted Indolopiperidine Derivatives as Potent CCR2B Receptor Antagonists 2001 ·Bioorganic & Medicinal Chemistry Letters ·Jason Witherington, Vincent Bordas, (unknown), Ian T. Forbes, Andrew D. Gribble, Robert J. Ife, Theo A. Berkhout, (unknown), Pieter H.E. Groot	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact